januar 31, 2025 0 37 CELEX:62023TO1181_INF: Order of the President of the General Court of 29 February 2024.#Mylan Ireland Ltd v European Commission.#Case T-1181/23 R.
marec 04, 2024 0 22 CELEX:62023TO1182: Order of the President of the General Court of 29 February 2024.#Neuraxpharm Pharmaceuticals SL v European Commission.#Case T-1182/23 R.
januar 31, 2025 0 21 CELEX:62023TO1182_INF: Order of the President of the General Court of 29 February 2024.#Neuraxpharm Pharmaceuticals SL v European Commission.#Case T-1182/23 R.
marec 04, 2024 0 21 CELEX:62023TO1183: Order of the President of the General Court of 29 February 2024.#Zakłady Farmaceutyczne Polpharma S.A. v European Commission.#Case T-1183/23 R.
januar 31, 2025 0 19 CELEX:62023TO1183_INF: Order of the President of the General Court of 29 February 2024.#Zakłady Farmaceutyczne Polpharma S.A. v European Commission.#Case T-1183/23 R.
marec 09, 2024 0 21 CELEX:62023TO1189: Order of the President of the General Court of 5 March 2024.#Identité et Démocratie Parti (ID Parti) v Authority for European Political Parties and European Political Foundations.#Case T-1189/23 R.
december 12, 2024 0 21 CELEX:62023TO1189_INF: Order of the President of the General Court of 5 March 2024.#Identité et Démocratie Parti (ID Parti) v Authority for European Political Parties and European Political Foundations.#Case T-1189/23 R.
november 12, 2024 0 34 CELEX:62023TO1194: Order of the General Court (Fifth Chamber) of 5 November 2024.#Apc Europe SL and Others v European Commission.#Case T-1194/23.
september 19, 2025 0 16 CELEX:62023TO1194_INF: Order of the General Court (Fifth Chamber) of 5 November 2024.#Apc Europe SL and Others v European Commission.#Case T-1194/23.
december 15, 2025 0 0 CELEX:62024CA0002: Case C-2/24 P: Judgment of the Court (Fourth Chamber) of 23 October 2025 – Teva Pharmaceutical Industries and Cephalon v Commission (Appeal – Competition – Article 101 TFEU – Agreements, decisions and concerted practices – Market for modafinil – Patent settlement agreement between two pharmaceutical companies for the purpose of delaying a generic version of modafinil being brought to the market – Decision finding an infringement of Article 101 TFEU – Criteria for assessment – Restriction by object)